Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk or hospitalization or death
Press Release (News), NCT05011513 (history)
, Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral.., Press Release (News), NCT05011513
EPIC-SR update reporting that the primary endpoint was not met. Minimal details are provided.
|
risk of death, 66.8% lower, RR 0.33, p = 0.50, treatment 0 of 576 (0.0%), control 1 of 569 (0.2%), NNT 569, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of ICU admission, 85.8% lower, RR 0.14, p = 0.12, treatment 0 of 576 (0.0%), control 3 of 569 (0.5%), NNT 190, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of death/hospitalization, 50.6% lower, RR 0.49, p = 0.20, treatment 5 of 576 (0.9%), control 10 of 569 (1.8%), NNT 112.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pfizer et al., 14 Jun 2022, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, trial NCT05011513 (history).
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.